Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 8Other solid neoplasm 4Genitourinary 4CNS 4Tumor-Agnostic 3Thoracic 3Sarcoma 3Gastrointestinal 3Breast 3Head & Neck 2

Conditions

Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
pamiparib × Genitourinary × Clear all
NCT06387056 2024-04-26

SEGNO

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
40 enrolled
Genitourinary

Locally Advanced Prostate Cancer

NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

NCT05327621 2022-04-14

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

BeiGene

Phase 2 Terminated
13 enrolled 11 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡